COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective …
AS Lauring, MW Tenforde, JD Chappell, M Gaglani… - bmj, 2022 - bmj.com
Objectives To characterize the clinical severity of covid-19 associated with the alpha, delta,
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …
Association between mRNA vaccination and COVID-19 hospitalization and disease severity
Importance A comprehensive understanding of the benefits of COVID-19 vaccination
requires consideration of disease attenuation, determined as whether people who develop …
requires consideration of disease attenuation, determined as whether people who develop …
Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
HM El Sahly, LR Baden, B Essink… - … England Journal of …, 2021 - Mass Medical Soc
Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
[HTML][HTML] Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults …
WH Self - MMWR. Morbidity and mortality weekly report, 2021 - cdc.gov
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson)
Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising …
Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising …
BNT162b2 protection against the omicron variant in children and adolescents
AM Price, SM Olson, MM Newhams… - … England Journal of …, 2022 - Mass Medical Soc
Background Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
B. 1.1. 529 (omicron) variant, which led to increased US hospitalizations for coronavirus …
B. 1.1. 529 (omicron) variant, which led to increased US hospitalizations for coronavirus …
Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents
Background The increasing incidence of pediatric hospitalizations associated with
coronavirus disease 2019 (Covid-19) caused by the B. 1.617. 2 (delta) variant of severe …
coronavirus disease 2019 (Covid-19) caused by the B. 1.617. 2 (delta) variant of severe …
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …
addition to those faced by the general population, including concerns about higher risks of …
Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US
Importance Persons with immune dysfunction have a higher risk for severe COVID-19
outcomes. However, these patients were largely excluded from SARS-CoV-2 vaccine …
outcomes. However, these patients were largely excluded from SARS-CoV-2 vaccine …